載入...
Risankizumab: A Review in Moderate to Severe Plaque Psoriasis
Risankizumab (Skyrizi(®); risankizumab-rzaa) is a humanized immunoglobulin (Ig) G1 monoclonal antibody that specifically targets the p19 subunit of interleukin (IL)-23, thereby inhibiting IL-23-dependent cell signaling. Subcutaneous risankizumab is approved for the treatment of adults with moderate...
Na minha lista:
| 發表在: | Drugs |
|---|---|
| 主要作者: | |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
Springer International Publishing
2020
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7475056/ https://ncbi.nlm.nih.gov/pubmed/32632826 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40265-020-01357-1 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|